AgomAb Therapeutics, a Belgian biotech focused on TGFβ inhibitors for fibrotic diseases, is set to raise $200 million through its IPO, offering 12.5 million shares priced between $15 and $17. The company is also developing a preclinical candidate for liver cirrhosis.

A CDC study reveals that over 60,000 patients in the U.S. were advised to get tested for hepatitis B and C due to lapses in infection control practices by healthcare personnel outside of hospitals. This highlights significant risks in patient safety and the need for improved adherence to infection protocols.

Acute viral hepatitis cases, specifically hepatitis A, B, and C, have significantly declined in the U.S. from 1995 to 2005, with hepatitis A and B reaching their lowest levels. This trend highlights the effectiveness of public health initiatives in managing these diseases.